KLRK1 and neoplasm: Hence, blocking NKG2D-mediated Vγ9Vδ2+ T-cell recognition of tumor cells with anti-NKG2D and anti-MICA/B monoclonal antibodies inhibits tumor cell killing to varying degrees (247, 249, 253).